Abstract

Objective: The Objective of this review is to evaluate the current available evidence for the efficacy of Magnesium sulphate in COPD.
Methodology: We undertook a literature review and metaanalysis aimed at identifying relevant articles regarding the use of magnesium (IV or nebulised) in the treatment of acute exacerbation of COPD. The outcome measures include; the effect on FEV1, FVC, PERF, rate of admission, rate of NIV or endotracheal intubation and in-hospital mortality.
Conclusion: It would appear that the addition of intravenous magnesium sulphate to the standard bronchodilator therapy for AECOPD is beneficial in terms of improving the respiratory functions, oxygen saturation and a reduction in hospital admission. There was no effect in the requirement for intubation and overall hospital mortality.